The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Jazz Pharmaceuticals plc shares valued at $113,210 were sold by COZADD BRUCE C on Aug 01 ’25. At $113.21 per share, COZADD BRUCE C sold 1,000 shares. The insider’s holdings dropped to 435,973 shares worth approximately $46.18 million following the completion of this transaction.
Also, COZADD BRUCE C purchased 9,000 shares, netting a total of over 1,096,210 in proceeds.
Before that, COZADD BRUCE C had sold 1,000 shares from its account. In a trade valued at $107,630, the Chairman & CEO traded Jazz Pharmaceuticals plc shares for $107.63 each. Upon closing the transaction, the insider’s holdings decreased to 1,000 shares, worth approximately $46.29 million.
As published in their initiating research note from Deutsche Bank on July 15, 2025, Jazz Pharmaceuticals plc [JAZZ] has been a Buy and the price target has been revised to $152. Analysts at UBS upgraded the stock from ‘”a Neutral”‘ to ‘”a Buy”‘ outlook in a report released in early March. As of February 26, 2025, Cantor Fitzgerald has decreased its “an Overweight” rating to a “Neutral” for JAZZ. Earlier on February 13, 2025, Wells Fargo upgraded its rating. Their new recommendation was “an Overweight” for JAZZ stock which previously was a “an Equal weight”.
Analyzing JAZZ Stock Performance
On last trading session, Jazz Pharmaceuticals plc [NASDAQ: JAZZ] plunged -6.42% to $105.93. The stock’s lowest price that day was $105.02, but it reached a high of $113.04 in the same session. During the last five days, there has been a drop of approximately -8.78%. Over the course of the year, Jazz Pharmaceuticals plc shares have dropped approximately -6.47%.
Is Jazz Pharmaceuticals plc subject to short interest?
Stocks of Jazz Pharmaceuticals plc saw a sharp steep in short interest on 2025-07-15 dropping by -0.1 million shares to 5.73 million. Data from Yahoo Finance shows that the short interest on 2025-06-13 was 5.83 million shares. A decline of -1.79% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 8.6 of the overall float, the days-to-cover ratio (short ratio) decline to 8.6.
Which companies own the most shares of Jazz Pharmaceuticals plc (JAZZ)?
In terms of Jazz Pharmaceuticals plc share price expectations, FactSet research, analysts set an average price target of 200 in the next 12 months, up nearly 76.68% from the previous closing price of $113.2. Analysts anticipate Jazz Pharmaceuticals plc stock to reach 230 by 2025, with the lowest price target being 152. In spite of this, 6 analysts ranked Jazz Pharmaceuticals plc stock as Buy at the end of 2025. On December 12, 2024, Morgan Stanley assigned a price target of “an Overweight” to the stock and upgraded coverage with a $175.
